Clinical Trials
24 trialsNCT05920356 2026-06-04
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
Phase 3 Recruiting
NCT06333951 2026-05-28
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
Phase 1 Active not recruiting
NCT07172919 2026-05-14
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
Phase 2 Recruiting
NCT04380753 2026-05-06
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
Amgen
Phase 1 Completed
NCT07563738 2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2 Recruiting
NCT04303780 2026-04-30
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
Amgen
Phase 3 Active not recruiting
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT06252649 2026-04-24
CodeBreaK 301
Amgen
Phase 3 Recruiting
NCT05036291 2026-04-22
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Ningbo Newbay Technology Development Co., Ltd
Phase 1 Terminated
NCT06497556 2026-04-20
Krascendo 1
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04892017 2026-04-08
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1 Terminated
NCT06804824 2026-03-18
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1 Recruiting
NCT03600883 2026-03-16
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Phase 1/2 Active not recruiting
NCT05074810 2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT04933695 2025-10-22
CodeBreaK201
Amgen
Phase 2 Completed
NCT05374538 2025-05-01
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Vitrac Therapeutics, LLC
Phase 1 Terminated
NCT04720976 2025-04-11
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05480865 2024-12-12
Argonaut
Navire Pharma Inc., a BridgeBio company
Phase 1 Terminated
NCT04092673 2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2 Unknown
NCT05180422 2023-10-18
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Criterium, Inc.
Phase 1/2 Withdrawn
NCT05045638 2023-08-14
Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
Amgen
Phase 1 Completed
NCT04959981 2023-07-25
HERKULES-2
Erasca, Inc.
Phase 1 Completed